Merck awards €1.25 million to research projects through its 2017 Grant for Fertility Innovation (GFI)

MerckMerck, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the advancement of medical science through the Grant for Fertility Innovation (GFI) in 2017. Launched as the first of the Merck Grants for Innovation in 2009, Merck's GFI is providing encouragement for innovation and support for scientists to realize projects that could potentially lead to the next breakthrough in the fertility treatment area. This year, the GFI Award Ceremony included the announcement of the Merck Lifetime Achievement Award in Fertility Innovation.

To recognize Merck's belief in progress through innovation, the GFI awardees were revealed in a ceremony at the European Society of Human Reproduction and Embryology (ESHRE), currently taking place in Geneva, Switzerland. The winning projects truly reflect the global nature of the program, ranging from research in Italy to Brazil.

Professor Bruno Lunenfeld, a speaker at the GFI 2017 ceremony, was honored with the Merck Lifetime Achievement Award for his revolutionary work within the fertility field since 1954. At the ceremony he provided an overview on the discovery of human gonadotropins from postmenopausal urine.

"Professor Lunenfeld's pioneering achievements in the field of fertility are a huge inspiration to us at Merck. It is highly motivating to consider the breadth of his contributions. For more than 60 years now, his expertise and experience have greatly contributed to our efforts to improve the quality of patient care," said Belén Garijo, member of the Executive Board of Merck and CEO Healthcare, when presenting Professor Lunenfeld with the Merck Lifetime Achievement Award.

The research investments through the GFI is core to the innovation strategy of the biopharma business of Merck, and in the quest for increased success rates within fertility treatment. In this year's GFI, two winning projects were selected from 46 global proposals with the common goal of advancing the fertility field. The GFI was launched in 2009, and is dedicated to transforming innovative translational fertility research projects into actual solutions with the aim to improve fertility treatment outcomes. Merck proudly announced the 2017 GFI awardees during the ceremony:

  • Endometrial Notch pathway as a novel target for improving implantation efficiency; Luisa Campagnolo, PhD
  • Pharmacogenetic algorithm for individualized controlled ovarian stimulation (iCOS) in assisted reproductive technology cycles; Caio Parente Barbosa, MD, PhD, MS and Matheus Roque, MD

About the Grant for Fertility Innovation (GFI)
Merck announced the initiation of the GFI program in 2009 to support the advancement of science and innovative technologies in the fertility field. This grant is awarded every year to translational research projects that can potentially improve baby birth rate for the benefit of the patients. Each project is blinded and evaluated by a jury of experts according to five criteria: support to increase baby birth rate; innovative research; scientific rationale; feasibility and practical utility.

For further information about the GFI and how to apply for next year’s grants, please visit: www.grantforfertilityinnovation.com

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]